NASDAQ:CNSP CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis $5.83 -0.03 (-0.51%) Closing price 08/19/2026 04:00 PM EasternExtended Trading$5.92 +0.09 (+1.63%) As of 08/19/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About CNS Pharmaceuticals Stock (NASDAQ:CNSP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CNS Pharmaceuticals alerts:Sign Up Key Stats Today's Range$5.70▼$6.1950-Day Range$4.03▼$5.8652-Week Range$1.90▼$10.59Volume21,426 shsAverage Volume6,760 shsMarket Capitalization$8.51 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingHold Company Overview CNS Pharmaceuticals, Inc., headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment. Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development. WP1066 is in preclinical stages with plans to progress to early-phase clinical studies, targeting patients who have limited treatment options due to the highly immunosuppressive nature of central nervous system tumors. Together, these candidates reflect the company’s strategy to address both direct cytotoxic and immune-mediated approaches to brain cancer therapy. Under the leadership of Chairman and Chief Executive Officer Howard J. Robin, CNS Pharmaceuticals completed its initial public offering on the NASDAQ Capital Market under the symbol CNSP. The company conducts clinical trials across North America and collaborates with academic and research institutions to support its development programs. With a dedicated focus on unmet needs in neuro-oncology, CNS Pharmaceuticals aims to advance its pipeline toward regulatory approvals and ultimately provide new treatment options for patients with life-threatening brain tumors.AI Generated. May Contain Errors. Read More CNS Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreCNSP MarketRank™: CNS Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCNS Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCNS Pharmaceuticals has a consensus price target of $20.00, representing about 243.1% upside from its current price of $5.83.Amount of Analyst CoverageCNS Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about CNS Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CNS Pharmaceuticals is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CNS Pharmaceuticals is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCNS Pharmaceuticals has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.78% of the float of CNS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCNS Pharmaceuticals has a short interest ratio ("days to cover") of 1.22, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CNS Pharmaceuticals has recently decreased by 27.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCNS Pharmaceuticals does not currently pay a dividend.Dividend GrowthCNS Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentCNS Pharmaceuticals has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for CNS Pharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for CNSP on MarketBeat in the last 30 days. MarketBeat Follows2 people have added CNS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.01% of the stock of CNS Pharmaceuticals is held by insiders.Percentage Held by Institutions14.02% of the stock of CNS Pharmaceuticals is held by institutions.Read more about CNS Pharmaceuticals' insider trading history. Receive CNSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNSP Stock News HeadlinesCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic TransformationAugust 12, 2026 | finanznachrichten.deCNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor PresentationJune 9, 2026 | markets.businessinsider.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. | Altimetry (Ad)CNS Pharmaceuticals (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic TransformationMay 15, 2026 | theglobeandmail.comForget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6May 14, 2026 | 247wallst.comWhat's going on with CNS Pharmaceuticals stock on Wednesday?May 6, 2026 | msn.comCNS Pharmaceuticals Announces Private Placement and Board ChangesMay 6, 2026 | theglobeandmail.comWhy did CNSP stock surge 330% today?May 5, 2026 | msn.comSee More Headlines CNSP Stock Analysis - Frequently Asked Questions How have CNSP shares performed this year? CNS Pharmaceuticals' stock was trading at $5.25 at the beginning of the year. Since then, CNSP shares have increased by 11.0% and is now trading at $5.83. How were CNS Pharmaceuticals' earnings last quarter? CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) released its earnings results on Wednesday, August, 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.14. When did CNS Pharmaceuticals' stock split? CNS Pharmaceuticals's stock reverse split on the morning of Friday, February 21st 2025.The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did CNS Pharmaceuticals IPO? CNS Pharmaceuticals (CNSP) raised $10 million in an initial public offering on Friday, November 8th 2019. The company issued 2,125,000 shares at $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO. Who are CNS Pharmaceuticals' major shareholders? Top institutional shareholders of CNS Pharmaceuticals include ADAR1 Capital Management LLC (4.79%) and Stonepine Capital Management LLC (2.85%). Insiders that own company stock include Michal Fisher and Christopher Downs. View institutional ownership trends. How do I buy shares of CNS Pharmaceuticals? Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CNS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO) and GE Aerospace (GE). Company Calendar Last Earnings8/12/2026Today8/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CNSP's financial health is in the Green zone, according to TradeSmith. CNSP has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CNSP CIK1729427 Webwww.cnspharma.com Phone800-946-9185FaxN/AEmployees5Year Founded2017Price Target and Rating Average Price Target for CNS Pharmaceuticals$20.00 High Price Target$20.00 Low Price Target$20.00 Potential Upside/Downside+243.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($23.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-204.25% Return on Assets-141.87% Debt Debt-to-Equity RatioN/A Current Ratio5.86 Quick Ratio5.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.45 per share Price / Book0.47Miscellaneous Outstanding Shares1,460,000Free Float1,461,000Market Cap$8.51 million OptionableNot Optionable Beta3.05 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CNSP) was last updated on 8/20/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThis tiny launch company operates next to SpaceX and Blue OriginA small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...Freedom Financial | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
